today announced it will be featured as a presenting company at the H.C. Wainwright 22nd Annual Global Investment Conference.
Biomica’s, a subsidiary of Evogene Ltd., live biotherapeutic drug candidate BMC128 administered in combination with Immune Checkpoint Inhibitors (ICI) significantly improved anti-tumor activity.
The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC426 and BMC427, for the treatment of IBS
Today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24, 2021.
The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials
